Back to Authors

Litvan, Irene

0000-0002-3485-3445

Mayo Clinic

Parkinson's Disease and Other Movement Disorders Center, University of California (UCSD), San Diego, California, USA.

Citations 18

α‐synuclein genetic variability: A biomarker for dementia in Parkinson disease
Guella, Ilaria, Evans, Daniel M. , Szu‐Tu, Chelsea , Nosova, Ekaterina , Bortnick, Stephanie, Group, SNCA Cognition Study, Goldman, Jennifer G. , Dalrymple‐Alford, John C. , Geurtsen, Gert J. , Litvan, Irene , Ross, Owen A. , Middleton, Lefkos , Farrer, Matthew J. , Group, SNCA Cognition Study, Parkkinen, Laura , Goldman, Jennifer G , Ross, Owen A , Dalrymple-Alford, John C , Geurtsen, Gert J , Litvan, Irene

Annals of Neurology | April 19, 2016 | Volume: 79 | Issue: 6 | Pages: 991-999

10.1002/ana.24664 Get It

ObjectiveThe relationship between Parkinson disease (PD), PD with dementia (PDD), and dementia with Lewy bodies (DLB) has long been debated. Although PD is primarily considered a motor disorder, cognitive impairment is often present at diagnosis, and only ∼20% of patients remain cognitively intact in the long term. Alpha‐synuclein (SNCA) was first implicated in the pathogenesis of the disease when point mutations and locus multiplications were identified in familial parkinsonism with dementia. In worldwide populations, SNCA genetic variability remains the most reproducible risk factor for idiopathic PD. However, few investigators have looked at SNCA variability in terms of cognitive outcomes.MethodsWe have used targeted high‐throughput sequencing to characterize the 135kb SNCA locus in a large multinational cohort of patients with PD, PDD, and DLB and healthy controls.ResultsAn analysis of 43 tagging single nucleotide polymorphisms across the SNCA locus shows 2 distinct association profiles for symptoms of parkinsonism and/or dementia, respectively, toward the 3′ or the 5′ of the SNCA gene. In addition, we define a specific haplotype in intron 4 that is directly associated with PDD. The PDD risk haplotype has been interrogated at single nucleotide resolution and is uniquely tagged by an expanded TTTCn repeat.InterpretationOur data show that PD, PDD, and DLB, rather than a disease continuum, have distinct genetic etiologies albeit within one genomic locus. Such results may serve as prognostic biomarkers to these disorders, to inform physicians and patients, and to assist in the design and stratification of clinical trials aimed at disease modification. Ann Neurol 2016;79:991–999
MDS research criteria for prodromal Parkinson's disease
Berg, Daniela , Bloem, Bastiaan R. , Dubois, Bruno, Gasser, Thomas , Halliday, Glenda M. , Joseph, Lawrence , Lang, Anthony E. , Liepelt‐Scarfone, Inga , Litvan, Irene , Marek, Kenneth , Oertel, Wolfgang H. , Olanow, C. Warren , Deuschl, Günther , Postuma, Ronald B. , Adler, Charles H. , Chan, Piu , Goetz, Christopher G. , Obeso, Jose Angel , Poewe, Werner H , Stern, Matthew , Halliday, Glenda , Lang, Anthony E , Deuschl, Günther , Litvan, Irene

Movement Disorders | October 16, 2015 | Volume: 30 | Issue: 12 | Pages: 1600-1611

10.1002/mds.26431 Get It

ABSTRACT This article describes research criteria and probability methodology for the diagnosis of prodromal PD. Prodromal disease refers to the stage wherein early symptoms or signs of PD neurodegeneration are present, but classic clinical diagnosis based on fully evolved motor parkinsonism is not yet possible. Given the lack of clear neuroprotective/disease‐modifying therapy for prodromal PD, these criteria were developed for research purposes only. The criteria are based upon the likelihood of prodromal disease being present with probable prodromal PD defined as ≥80% certainty. Certainty estimates rely upon calculation of an individual's risk of having prodromal PD, using a Bayesian naïve classifier. In this methodology, a previous probability of prodromal disease is delineated based upon age. Then, the probability of prodromal PD is calculated by adding diagnostic information, expressed as likelihood ratios. This diagnostic information combines estimates of background risk (from environmental risk factors and genetic findings) and results of diagnostic marker testing. In order to be included, diagnostic markers had to have prospective evidence documenting ability to predict clinical PD. They include motor and nonmotor clinical symptoms, clinical signs, and ancillary diagnostic tests. These criteria represent a first step in the formal delineation of early stages of PD and will require constant updating as more information becomes available. © 2015 International Parkinson and Movement Disorder Society
MDS clinical diagnostic criteria for Parkinson's disease
Berg, Daniela , Olanow, C. Warren , Oertel, Wolfgang H. , Marek, Kenneth , Litvan, Irene , Lang, Anthony E. , Halliday, Glenda M. , Gasser, Thomas , Dubois, Bruno, Bloem, Bastiaan R. , Deuschl, Günther , Postuma, Ronald B. , Stern, Matthew , Poewe, Werner H , Obeso, Jose Angel , Goetz, Christopher G. , Chan, Piu , Adler, Charles H. , Halliday, Glenda , Lang, Anthony E , Deuschl, Günther , Litvan, Irene

Movement Disorders | October 16, 2015 | Volume: 30 | Issue: 12 | Pages: 1591-1601

10.1002/mds.26424 Get It

AbstractThis document presents the Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's disease (PD). The Movement Disorder Society PD Criteria are intended for use in clinical research but also may be used to guide clinical diagnosis. The benchmark for these criteria is expert clinical diagnosis; the criteria aim to systematize the diagnostic process, to make it reproducible across centers and applicable by clinicians with less expertise in PD diagnosis. Although motor abnormalities remain central, increasing recognition has been given to nonmotor manifestations; these are incorporated into both the current criteria and particularly into separate criteria for prodromal PD. Similar to previous criteria, the Movement Disorder Society PD Criteria retain motor parkinsonism as the core feature of the disease, defined as bradykinesia plus rest tremor or rigidity. Explicit instructions for defining these cardinal features are included. After documentation of parkinsonism, determination of PD as the cause of parkinsonism relies on three categories of diagnostic features: absolute exclusion criteria (which rule out PD), red flags (which must be counterbalanced by additional supportive criteria to allow diagnosis of PD), and supportive criteria (positive features that increase confidence of the PD diagnosis). Two levels of certainty are delineated: clinically established PD (maximizing specificity at the expense of reduced sensitivity) and probable PD (which balances sensitivity and specificity). The Movement Disorder Society criteria retain elements proven valuable in previous criteria and omit aspects that are no longer justified, thereby encapsulating diagnosis according to current knowledge. As understanding of PD expands, the Movement Disorder Society criteria will need continuous revision to accommodate these advances. © 2015 International Parkinson and Movement Disorder Society
A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease
Investigators, The Parkinson Study Group QE3, Beal, M. Flint, Oakes, David , Shoulson, Ira , Henchcliffe, Claire , Galpern, Wendy R., Haas, Richard , Juncos, Jorge L., Nutt, John G. , Voss, Tiffini, Ravina, Bernard, Shults, Clifford M., Helles, Karen, Snively, Victoria, Lew, Mark, Griebner, Brian, Watts, Arthur, Gao, Shan , Pourcher, Emmanuelle, Bond, Louisette, Kompoliti, Katie , Sia, Cherissa, Jog, Mandar , Sultana, Munira , Kurlan, Roger, Richard, Irene Hegeman, Deeley, Cheryl, Waters, Cheryl , Figueroa, Angel, Arkun, Ani, Brodsky, Matthew , Ondo, William G. , Hunter, Christine , Jimenez‐Shahed, Joohi , Palao, Alicia, Miyasaki, Janis M. , So, Julie , Tetrud, James W., Reys, Liza, Singer, Carlos , Blenke, Anita, Russell, David , Cotto, Candace, Lannon, Margaret C., Drasby, Edward, Kumar, Rajeev , Subramanian, Thyagarajan , Ford, Donna Stuppy, Grimes, David A. , Côté, Diane , Conway, Jennifer, Siderowf, Andrew , Evatt, Marian L., Sommerfeld, Barbara, Lieberman, Abraham, Okun, Michael S. , Rodriguez, Ramon L. , Merritt, Stacy, Swartz, Camille, Martin, W. R. Wayne , King, Pamela, Stover, Natividad , Guthrie, Stephanie, Watts, Ray L., Fernandez, Hubert H. , Winters, Adrienna, Dawson, Ted M. , Dunlop, Becky, Feigin, Andrew, Shannon, Barbara , Nirenberg, Melissa J. , Ogg, Mattson , Ellias, Samuel A., Thomas, Cathi-Ann, Frei, Karen , Bódis-Wollner, Iván , Glazman, Sofya, Mayer, Thomas A. , Hauser, Robert A. , Langhammer, April, Ranawaya, Ranjit, Derwent, Lorelei, Farrow, Buff, Prakash, Rajan , Litvan, Irene , Robinson, Annette, Sahay, Alok , Gartner, Maureen, Markind, Samuel, Pelikan, Melisa, Hartlein, Johanna M, Molho, Eric , Evans, Sharon, Duffy, Amy, Lind, Marlene, Elmer, Lawrence , Davis, Kathy, Spears, Julia, Leehey, Maureen A. , Hermanowicz, Neal , Niswonger, Shari, Shill, Holly A. , Obradov, Sanja, Rajput, Alex, Cowper, Marilyn, Lessig, Stephanie, Fontaine, Deborah, Zadikoff, Cindy , Williams, Karen, Blindauer, Karen, Bergholte, Jo, Propsom, Clara Schindler, Stacy, Mark, Field, Joanne, Mihaila, Dragos, Chilton, Mark, Uc, Ergun Y., Sieren, Jeri, Simon, David K. , Kraics, Lauren, Silver, Althea, Boyd, James T. , Hamill, Robert W., Ingvoldstad, Christopher T., Young, Jennifer , Thomas, Karen, Kostyk, Sandra K. , Wojcieszek, Joanne, Pfeiffer, Ronald F. , Panisset, Michel , Beland, Monica, Reich, Stephen G. , Cines, Michelle, Zappala, Nancy, Rivest, J., Zweig, Richard M., Lumina, L. Pepper, Hilliard, Colette Lynn, Grill, Stephen , Kellermann, Marye, Tuite, Paul , Rolandelli, Susan, Kang, Un Jung , Young, Joan, Rao, Jayaraman, Cook, Maureen, Severt, Lawrence, Boyar, Karyn, Scott, Ingrid U. , Investigators, The Parkinson Study Group QE3, Beal, M. Flint , Agarwal, Pinky , Cole, Linda C. , Smith, Katharine , Friedman, Joseph H. , Zhang, Lin , Ahmed, Anwar E. , Mari, Zoltan K. , Pahwa, Rajesh , Sethi, Kapil D. , Hinson, Vanessa K. , Perlmutter, Joel S. , Adler, Charles H. , Wilson, Stephanie M. G. , Song, David , Williams, Karen, Uc, Ergun Y., Okun, Michael S , Litvan, Irene , Hauser, Robert A , Jimenez-Shahed, Joohi

JAMA Neurology | March 25, 2014 | Volume: 71 | Issue: 5 | Pages: 543

10.1001/jamaneurol.2014.131 Get It

Clinical and Genetic Aspects of Progressive Supranuclear Palsy
Litvan, Irene , Hutton, Michael , Litvan, Irene

Journal of Geriatric Psychiatry and Neurology | March 18, 2014 | Volume: 11 | Issue: 2 | Pages: 107-114

10.1177/089198879801100208 Get It

Progressive supranuclear palsy (PSP) is, after Parkinson's disease, the most common form of degenerative parkinsonism. Several clinical features are used in the recognition of this disorder as well as in the differentiation from related disorders. Clinical criteria that could increase diagnostic accuracy in research studies are also emphasized. Due to a better understanding of the genetic aspects of PSP, recent studies have suggested that it is a recessive disorder in linkage disequilibrium with the tau (τ) gene, rather than a sporadic disorder. In addition, the recent identification of mutations in the τ gene associated with a similar neurodegenerative condition (frontotemporal dementia and parkinsonism linked to chromosome 17) has further strengthened the argument that τ dysfunction is somehow involved in the pathogenesis of PSP. Nongenetic factors that could trigger or perpetuate the cascade of events leading to neuronal degeneration in PSP are also reviewed.
Tau genotype: No effect on onset, symptom severity, or survival in progressive supranuclear palsy
Litvan, Irene , Baker, Matt , Hutton, Michael , Litvan, Irene

Neurology | May 13, 2012 | Volume: 57 | Issue: 1 | Pages: 138-140

10.1212/wnl.57.1.138 Get It